



The relative strengths and weaknesses of HH Biotechnology Holdings CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HH Biotechnology Holdings CO compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 25% points. The greatest weakness of HH Biotechnology Holdings CO is the variable Liabilities, Current, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 54%, being 27% points below the market average of 81%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Cost of Revenue	5,047	Real Estate Investments, Net	0
Depreciation and Amortization	19	Liabilities	35,543
General and Administrative Expense	1,829	Assets	59,555
Goodwill and Intangible Assets	0	Revenues	5,580
Lease Income	5,580	Expenses	8,351
Liabilities, Current	35,543	Stockholders Equity	24,012
Liabilities, Long-term	0	Net Income	-1,814
Other Assets	59,555	Comprehensive Net Income	-1,461
Other Compr. Net Income	707	ECR before Limited Liability	29%
Other Expenses	1,457	Economic Capital Ratio	54%
Other Liabilities	0		
Other Net Income	957		
Other Real Estate Investments, Net	0		
Other Revenues	0		
Real Estate Investment Property, Accumulated Depreciation	0		
Real Estate Investment Property, at Cost	0		